Literature DB >> 25606362

Modeling fragile X syndrome in the Fmr1 knockout mouse.

Tatiana M Kazdoba1, Prescott T Leach1, Jill L Silverman1, Jacqueline N Crawley1.   

Abstract

Fragile X Syndrome (FXS) is a commonly inherited form of intellectual disability and one of the leading genetic causes for autism spectrum disorder. Clinical symptoms of FXS can include impaired cognition, anxiety, hyperactivity, social phobia, and repetitive behaviors. FXS is caused by a CGG repeat mutation which expands a region on the X chromosome containing the FMR1 gene. In FXS, a full mutation (> 200 repeats) leads to hypermethylation of FMR1, an epigenetic mechanism that effectively silences FMR1 gene expression and reduces levels of the FMR1 gene product, fragile X mental retardation protein (FMRP). FMRP is an RNA-binding protein that is important for the regulation of protein expression. In an effort to further understand how loss of FMR1 and FMRP contribute to FXS symptomology, several FXS animal models have been created. The most well characterized rodent model is the Fmr1 knockout (KO) mouse, which lacks FMRP protein due to a disruption in its Fmr1 gene. Here, we review the behavioral phenotyping of the Fmr1 KO mouse to date, and discuss the clinical relevance of this mouse model to the human FXS condition. While much remains to be learned about FXS, the Fmr1 KO mouse is a valuable tool for understanding the repercussions of functional loss of FMRP and assessing the efficacy of pharmacological compounds in ameliorating the molecular and behavioral phenotypes relevant to FXS.

Entities:  

Keywords:  Fmr1 knockout mouse; Fragile X Syndrome; anxiety; attention; behavior; cognition; phenotyping; social behaviors

Year:  2014        PMID: 25606362      PMCID: PMC4298642          DOI: 10.5582/irdr.2014.01024

Source DB:  PubMed          Journal:  Intractable Rare Dis Res        ISSN: 2186-3644


  208 in total

Review 1.  LTP and LTD: an embarrassment of riches.

Authors:  Robert C Malenka; Mark F Bear
Journal:  Neuron       Date:  2004-09-30       Impact factor: 17.173

2.  Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey.

Authors:  Donald B Bailey; Melissa Raspa; Ellen Bishop; Murrey Olmsted; Usha G Mallya; Elizabeth Berry-Kravis
Journal:  J Dev Behav Pediatr       Date:  2012-01       Impact factor: 2.225

3.  Hippocampal lesions cause learning deficits in inbred mice in the Morris water maze and conditioned-fear task.

Authors:  S F Logue; R Paylor; J M Wehner
Journal:  Behav Neurosci       Date:  1997-02       Impact factor: 1.912

4.  Mildly impaired water maze performance in male Fmr1 knockout mice.

Authors:  R D'Hooge; G Nagels; F Franck; C E Bakker; E Reyniers; K Storm; R F Kooy; B A Oostra; P J Willems; P P De Deyn
Journal:  Neuroscience       Date:  1997-01       Impact factor: 3.590

5.  Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse.

Authors:  Yann S Mineur; Frans Sluyter; Sanne de Wit; Ben A Oostra; Wim E Crusio
Journal:  Hippocampus       Date:  2002       Impact factor: 3.899

6.  Epilepsy and EEG findings in males with fragile X syndrome.

Authors:  S A Musumeci; R J Hagerman; R Ferri; P Bosco; B Dalla Bernardina; C A Tassinari; G B De Sarro; M Elia
Journal:  Epilepsia       Date:  1999-08       Impact factor: 5.864

7.  Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome.

Authors:  Elena D Nosyreva; Kimberly M Huber
Journal:  J Neurophysiol       Date:  2006-02-01       Impact factor: 2.714

8.  FMR1 protein: conserved RNP family domains and selective RNA binding.

Authors:  C T Ashley; K D Wilkinson; D Reines; S T Warren
Journal:  Science       Date:  1993-10-22       Impact factor: 47.728

9.  Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome.

Authors:  Caitlyn H McNaughton; Jisook Moon; Myla S Strawderman; Kenneth N Maclean; Jeffrey Evans; Barbara J Strupp
Journal:  Behav Neurosci       Date:  2008-04       Impact factor: 1.912

Review 10.  Phenotypic variation and FMRP levels in fragile X.

Authors:  Danuta Z Loesch; Richard M Huggins; Randi J Hagerman
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2004
View more
  87 in total

1.  Chd8 Mutation Leads to Autistic-like Behaviors and Impaired Striatal Circuits.

Authors:  Randall J Platt; Yang Zhou; Ian M Slaymaker; Ashwin S Shetty; Niels R Weisbach; Jin-Ah Kim; Jitendra Sharma; Mitul Desai; Sabina Sood; Hannah R Kempton; Gerald R Crabtree; Guoping Feng; Feng Zhang
Journal:  Cell Rep       Date:  2017-04-11       Impact factor: 9.423

Review 2.  The epitranscriptome and synaptic plasticity.

Authors:  Mathieu N Flamand; Kate D Meyer
Journal:  Curr Opin Neurobiol       Date:  2019-05-17       Impact factor: 6.627

3.  The RNA-binding protein, ZC3H14, is required for proper poly(A) tail length control, expression of synaptic proteins, and brain function in mice.

Authors:  Jennifer Rha; Stephanie K Jones; Jonathan Fidler; Ayan Banerjee; Sara W Leung; Kevin J Morris; Jennifer C Wong; George Andrew S Inglis; Lindsey Shapiro; Qiudong Deng; Alicia A Cutler; Adam M Hanif; Machelle T Pardue; Ashleigh Schaffer; Nicholas T Seyfried; Kenneth H Moberg; Gary J Bassell; Andrew Escayg; Paul S García; Anita H Corbett
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

4.  Nanoparticle delivery of CRISPR into the brain rescues a mouse model of fragile X syndrome from exaggerated repetitive behaviours.

Authors:  Bumwhee Lee; Kunwoo Lee; Shree Panda; Rodrigo Gonzales-Rojas; Anthony Chong; Vladislav Bugay; Hyo Min Park; Robert Brenner; Niren Murthy; Hye Young Lee
Journal:  Nat Biomed Eng       Date:  2018-06-25       Impact factor: 25.671

5.  Kinase pathway inhibition restores PSD95 induction in neurons lacking fragile X mental retardation protein.

Authors:  Ying Yang; Yang Geng; Dongyun Jiang; Lin Ning; Hyung Joon Kim; Noo Li Jeon; Anthony Lau; Lu Chen; Michael Z Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-22       Impact factor: 11.205

6.  Decreased home cage movement and oromotor impairments in adult Fmr1-KO mice.

Authors:  S J Bonasera; T R Chaudoin; E H Goulding; M Mittek; A Dunaevsky
Journal:  Genes Brain Behav       Date:  2017-03-29       Impact factor: 3.449

Review 7.  Emerging roles for MEF2 in brain development and mental disorders.

Authors:  Ahlem Assali; Adam J Harrington; Christopher W Cowan
Journal:  Curr Opin Neurobiol       Date:  2019-05-23       Impact factor: 6.627

Review 8.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

9.  Potential Involvement of Impaired BKCa Channel Function in Sensory Defensiveness and Some Behavioral Disturbances Induced by Unfamiliar Environment in a Mouse Model of Fragile X Syndrome.

Authors:  Maria Isabel Carreno-Munoz; Fabienne Martins; Maria Carmen Medrano; Elisabetta Aloisi; Susanna Pietropaolo; Corentin Dechaud; Enejda Subashi; Guillaume Bony; Melanie Ginger; Abdelmalik Moujahid; Andreas Frick; Xavier Leinekugel
Journal:  Neuropsychopharmacology       Date:  2017-07-19       Impact factor: 7.853

Review 10.  The role of ARID1B, a BAF chromatin remodeling complex subunit, in neural development and behavior.

Authors:  Jeffrey J Moffat; Eui-Man Jung; Minhan Ka; Amanda L Smith; Byeong Tak Jeon; Gijs W E Santen; Woo-Yang Kim
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-08-24       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.